Zydus has wasted no time in announcing the launch of its nivolumab biosimilar, Tishtha™, on 22 January 2026, following the High Court of Delhi’s 12 January 2026 reversal on appeal of a preliminary injunction granted to BMS in relation to the biosimilar.
Zydus’ nivolumab biosimilar, previously referred to as ZRC-3276, received regulatory approval in India in July 2024. It is the first nivolumab biosimilar in the world to reach the market and is priced at about one quarter the cost of the reference product, BMS’ Opdivo® (sold in India as Opdyta®).
Competing nivolumab biosimilars are under development for the Indian market by Enzene and Reliance Life Sciences. Globally, Amgen, Sandoz, Xbrane/Intas, Boan Biotech, Shanghai Henlius and Biocon also have nivolumab biosimilars under development.